

October 18, 2016

Hiberix® Approved as a 3-dose Primary Vaccine

Effective immediately Hiberix® (*Haemophilus influenzae* type b vaccine) is now available through the Philadelphia Vaccines For Children (VFC) Program.

Earlier this year, the Food and Drug Administration (FDA) approved Hiberix® for a 3-dose infant primary vaccination series at ages 2, 4, and 6 months. A single booster dose should be administered to children 15 through 18 months of age.

More information about Hiberix® and the updated recommendation can be found on the [Vaccine Information Statement](#) and the [MMWR](#).